Yael Peled
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yael Peled has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Eilon Ram
Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA
16 shared publications Jacob Lavee
Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel
16 shared publicationsDov Freimark
Heart Transplantation Unit, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Israel; Sackler School of Medicine, Tel Aviv University, Israel
14 shared publicationsYigal Kassif
Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Hashomer, Israel
13 shared publicationsMichal Mandelboim
Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel; Central Virology Laboratory, Ministry of Health, Tel-Hashomer, Israel
11 shared publicationsEhud Raanani
Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Ramat Gan, Israel; Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
10 shared publications
Latest Publications
- 1 September 2025
- Published by Springer Nature
- p. 395-399
Patient Selection in the Context of Organ Scarcity
- 1 September 2025
- Published by Springer Nature
- p. 395-399
Patient Selection in the Context of Organ Scarcity
- 1 September 2025
- Published by Springer Nature
- p. 207-226
COVID-19 Considerations in Heart Transplantation
- 1 September 2025
- Published by Springer Nature
- p. 207-226
COVID-19 Considerations in Heart Transplantation
- Top Cited Papers
- 8 August 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (10) , 1529-1628.e54
International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024
- 8 August 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (10) , 1529-1628.e54
Top Cited PapersInternational Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024
- 3 May 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (8) , 1263-1265
Discovering the Limits of the Possible: Two Can Play That Game
- 3 May 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (8) , 1263-1265
Discovering the Limits of the Possible: Two Can Play That Game
- 24 March 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (7) , 1188-1192
Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients
- 24 March 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (7) , 1188-1192
Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients
- 26 February 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (8) , 902-911
The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices
Background: The safety and impact of sodium glucose transporter 2 inhibitors (SGLT2‐I) in patients with left ventricular assist devices (LVAD) are unknown.Methods: A retrospective analysis of all consecutive patients who underwent LVAD Heart Mate 3 (HM3) implantation at a single medical center and received SGLT2‐I therapy following surgery was conducted. LVAD parameters, medical therapy, laboratory tests, echocardiography, and right heart catheterization (RHC) study results were recorded and compared before and after initiation of SGLT2‐I.Results: SGLT2‐I medications were initiated in 29 (21%) of 138 patients following HM3 implantation (23 (79%) received Empagliflozin and 6 (21%) Dapagliflozin). The mean age at the time of LVAD implantation was 62 ± 6.7 years, 25 (86%) were male, and 23 (79%) had diabetes mellitus. The median time from HM3 implantation to SGLT2‐I initiation was 108 days, IQR (26–477). Following SGLT2‐I therapy, the daily dose of furosemide decreased from 47 to 23.5 mg/day (mean difference = 23.5 mg/d, 95% CI 8.2–38.7, p = 0.004) and significant weight reduction was observed (mean difference 2.5 kg, 95% CI 0.7–4.3, p = 0.008). Moreover, a significant 5.6 mm Hg reduction in systolic pulmonary artery pressure (sPAP) was measured during RHC (95% CI 0.23–11, p = 0.042) in a subgroup of 11 (38%) patients. LVAD parameters were similar before and after SGLT2‐I initiation (p > 0.2 for all). No adverse events were recorded during median follow‐up of 354 days, IQR (206–786).Conclusion: SGLT2‐I treatment is safe in LVAD patients and might contribute to reduction in patients sPAP.
- 26 February 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (8) , 902-911
The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices
Background: The safety and impact of sodium glucose transporter 2 inhibitors (SGLT2‐I) in patients with left ventricular assist devices (LVAD) are unknown.Methods: A retrospective analysis of all consecutive patients who underwent LVAD Heart Mate 3 (HM3) implantation at a single medical center and received SGLT2‐I therapy following surgery was conducted. LVAD parameters, medical therapy, laboratory tests, echocardiography, and right heart catheterization (RHC) study results were recorded and compared before and after initiation of SGLT2‐I.Results: SGLT2‐I medications were initiated in 29 (21%) of 138 patients following HM3 implantation (23 (79%) received Empagliflozin and 6 (21%) Dapagliflozin). The mean age at the time of LVAD implantation was 62 ± 6.7 years, 25 (86%) were male, and 23 (79%) had diabetes mellitus. The median time from HM3 implantation to SGLT2‐I initiation was 108 days, IQR (26–477). Following SGLT2‐I therapy, the daily dose of furosemide decreased from 47 to 23.5 mg/day (mean difference = 23.5 mg/d, 95% CI 8.2–38.7, p = 0.004) and significant weight reduction was observed (mean difference 2.5 kg, 95% CI 0.7–4.3, p = 0.008). Moreover, a significant 5.6 mm Hg reduction in systolic pulmonary artery pressure (sPAP) was measured during RHC (95% CI 0.23–11, p = 0.042) in a subgroup of 11 (38%) patients. LVAD parameters were similar before and after SGLT2‐I initiation (p > 0.2 for all). No adverse events were recorded during median follow‐up of 354 days, IQR (206–786).Conclusion: SGLT2‐I treatment is safe in LVAD patients and might contribute to reduction in patients sPAP.
- Open Access
- 12 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (11) , e15091
BNT162b2‐vaccine‐induced neutralization responses are immune correlates of clinical protection against SARS‐CoV‐2 in heart transplant recipients
Background: Defining immune correlates of protection against COVID‐19 is pivotal for optimizing the use of COVID‐19 vaccines, predicting the impact of novel variants on clinical outcomes, and advancing the development of immunotherapies and next‐generation vaccines. We aimed to identify vaccine‐induced immune correlates of protection against COVID‐19‐related hospitalizations in a highly vaccinated heart transplant (HT) cohort.Methods: In a case‐control study of HT recipients vaccinated with the BNT162b2 vaccine, patients were prospectively assessed for vaccine‐induced neutralization of the wild‐type virus, and the Delta and Omicron BA.1, BA.2, BA.4, and BA.5 variants. Comparative analyses with controls were conducted to identify correlates of protection against COVID‐19 hospitalization. ROC analyses were performed. Primary outcomes were COVID‐19 hospitalizations and severity of SARS‐CoV‐2 breakthrough infection.Results: The study cohort comprised 59 HT recipients aged 58 (49,65) years with breakthrough infections after three or four monovalent BNT162b2 doses; 41 (69.5%) were men. Thirty‐six (61%) patients with COVID‐19 were hospitalized; most cases were non‐severe (58, 98%). For hospitalized (vs. non‐hospitalized) COVID‐19 patients, vaccine‐induced neutralization titers were significantly lower against all SARS‐CoV‐2 variants (p < .005). Vaccine‐induced neutralization of the wild‐type virus and delta and omicron BA.1, BA.2, BA.4, and BA.5 variants was associated with a reduced risk for COVID‐19‐related hospitalization. The optimal neutralization titer thresholds that were predictive of COVID‐19 hospitalizations were 96 (wild‐type), 48 (delta), 12 (BA.1), 96 (BA.2), 96 (BA.4), and 48 (BA.5).Conclusions: BNT162b2‐vaccine‐induced neutralization responses are immune correlates of protection and confer clinical protection against COVID‐19 hospitalizations.
- 12 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (11) , e15091
Open AccessBNT162b2‐vaccine‐induced neutralization responses are immune correlates of clinical protection against SARS‐CoV‐2 in heart transplant recipients
Background: Defining immune correlates of protection against COVID‐19 is pivotal for optimizing the use of COVID‐19 vaccines, predicting the impact of novel variants on clinical outcomes, and advancing the development of immunotherapies and next‐generation vaccines. We aimed to identify vaccine‐induced immune correlates of protection against COVID‐19‐related hospitalizations in a highly vaccinated heart transplant (HT) cohort.Methods: In a case‐control study of HT recipients vaccinated with the BNT162b2 vaccine, patients were prospectively assessed for vaccine‐induced neutralization of the wild‐type virus, and the Delta and Omicron BA.1, BA.2, BA.4, and BA.5 variants. Comparative analyses with controls were conducted to identify correlates of protection against COVID‐19 hospitalization. ROC analyses were performed. Primary outcomes were COVID‐19 hospitalizations and severity of SARS‐CoV‐2 breakthrough infection.Results: The study cohort comprised 59 HT recipients aged 58 (49,65) years with breakthrough infections after three or four monovalent BNT162b2 doses; 41 (69.5%) were men. Thirty‐six (61%) patients with COVID‐19 were hospitalized; most cases were non‐severe (58, 98%). For hospitalized (vs. non‐hospitalized) COVID‐19 patients, vaccine‐induced neutralization titers were significantly lower against all SARS‐CoV‐2 variants (p < .005). Vaccine‐induced neutralization of the wild‐type virus and delta and omicron BA.1, BA.2, BA.4, and BA.5 variants was associated with a reduced risk for COVID‐19‐related hospitalization. The optimal neutralization titer thresholds that were predictive of COVID‐19 hospitalizations were 96 (wild‐type), 48 (delta), 12 (BA.1), 96 (BA.2), 96 (BA.4), and 48 (BA.5).Conclusions: BNT162b2‐vaccine‐induced neutralization responses are immune correlates of protection and confer clinical protection against COVID‐19 hospitalizations.
- 12 August 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (11) , 1489-1492
Two negatives make a positive: Maximizing heart procurement in adult congenital heart disease
- 12 August 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (11) , 1489-1492
Two negatives make a positive: Maximizing heart procurement in adult congenital heart disease
- 11 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (11) , e15092
Neutralization of SARS‐CoV‐2 variants elicited by the combination of vaccination and natural infection in heart transplant recipients
- 11 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (11) , e15092
Neutralization of SARS‐CoV‐2 variants elicited by the combination of vaccination and natural infection in heart transplant recipients
- 19 April 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (8) , 1054-1058
Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients
- 19 April 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (8) , 1054-1058
Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients